ViewRay (VRAY) Stock Forecast, Price Target & Predictions
VRAY Stock Forecast
ViewRay stock forecast is as follows: an average price target of $6.25 (represents a 44542.86% upside from VRAY’s last price of $0.01) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VRAY Price Target
The average price target for ViewRay (VRAY) is $6.25 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $4.00. This represents a potential 44542.86% upside from VRAY's last price of $0.01.
VRAY Analyst Ratings
According to 2 Wall Street analysts, ViewRay's rating consensus is 'Buy'. The analyst rating breakdown for VRAY stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ViewRay Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 02, 2022 | Jason Bednar | Piper Sandler | $6.00 | $3.00 | 100.00% | 42757.14% |
| Jun 24, 2022 | - | BTIG | $8.00 | $2.80 | 185.71% | 57042.86% |
| May 09, 2022 | - | Morgan Stanley | $4.00 | $2.40 | 66.67% | 28471.43% |
| May 06, 2022 | - | Piper Sandler | $7.00 | $2.50 | 180.00% | 49900.00% |
| Jan 25, 2022 | Rick Wise | Stifel Nicolaus | $7.00 | $4.41 | 58.73% | 49900.00% |
The latest ViewRay stock forecast, released on Aug 02, 2022 by Jason Bednar from Piper Sandler, set a price target of $6.00, which represents a 100.00% increase from the stock price at the time of the forecast ($3.00), and a 42757.14% increase from VRAY last price ($0.01).
ViewRay Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.01 | $0.01 | $0.01 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of ViewRay stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ViewRay's last price of $0.01. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 02, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 24, 2022 | BTIG | Buy | Buy | Hold |
ViewRay's last stock rating was published by Piper Sandler on Aug 02, 2022. The company gave VRAY a "Overweight" rating, the same as its previous rate.
ViewRay Financial Forecast
ViewRay Revenue Forecast
| Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $22.53M | $34.69M | $18.88M | $15.53M | $14.25M | $20.28M | $26.19M | $1.23M | $5.46M |
| Avg Forecast | $21.74M | $19.76M | $22.00M | $15.62M | $15.53M | $13.50M | $13.12M | $47.62M | $501.11K | $4.68M |
| High Forecast | $26.08M | $23.71M | $26.40M | $18.74M | $18.63M | $16.20M | $15.75M | $57.14M | $601.33K | $5.62M |
| Low Forecast | $17.39M | $15.81M | $17.60M | $12.50M | $12.42M | $10.80M | $10.50M | $38.09M | $400.89K | $3.74M |
| # Analysts | 17 | 13 | 18 | 19 | 9 | 19 | 9 | 14 | 11 | 12 |
| Surprise % | - | 1.14% | 1.58% | 1.21% | 1.00% | 1.06% | 1.55% | 0.55% | 2.45% | 1.17% |
ViewRay's average Quarter revenue forecast for Mar 24 based on 17 analysts is $21.74M, with a low forecast of $17.39M, and a high forecast of $26.08M. VRAY's average Quarter revenue forecast represents a -3.54% decrease compared to the company's last Quarter revenue of $22.53M (Mar 23).
ViewRay EBITDA Forecast
| Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 17 | 13 | 18 | 19 | 9 | 19 | 9 | 14 | 11 | 12 |
| EBITDA | - | $-26.23M | $-25.52M | $-23.47M | $-24.04M | $-25.03M | $-31.66M | $-2.29M | $-25.76M | $-11.91M |
| Avg Forecast | $-36.73M | $-33.40M | $-27.13M | $-26.40M | $-24.04M | $-23.64M | $-15.83M | $-2.99M | $-12.88M | $-9.93M |
| High Forecast | $-29.39M | $-26.72M | $-21.71M | $-21.12M | $-19.23M | $-18.91M | $-12.66M | $-2.39M | $-10.30M | $-7.94M |
| Low Forecast | $-44.08M | $-40.07M | $-32.56M | $-31.68M | $-28.84M | $-28.37M | $-18.99M | $-3.59M | $-15.45M | $-11.91M |
| Surprise % | - | 0.79% | 0.94% | 0.89% | 1.00% | 1.06% | 2.00% | 0.77% | 2.00% | 1.20% |
undefined analysts predict VRAY's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ViewRay's previous annual EBITDA (undefined) of $NaN.
ViewRay Net Income Forecast
| Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 17 | 13 | 18 | 19 | 9 | 19 | 9 | 14 | 11 | 12 |
| Net Income | - | $-30.71M | $-27.87M | $-24.07M | $-26.74M | $-27.53M | $-33.36M | $-4.81M | $-27.96M | $-13.37M |
| Avg Forecast | $-40.35M | $-36.68M | $-29.77M | $-29.00M | $-26.74M | $-26.00M | $-16.68M | $-6.28M | $-13.98M | $-11.14M |
| High Forecast | $-32.28M | $-29.34M | $-23.82M | $-23.20M | $-21.39M | $-20.80M | $-13.34M | $-5.03M | $-11.18M | $-8.91M |
| Low Forecast | $-48.42M | $-44.02M | $-35.73M | $-34.79M | $-32.09M | $-31.20M | $-20.02M | $-7.54M | $-16.78M | $-13.37M |
| Surprise % | - | 0.84% | 0.94% | 0.83% | 1.00% | 1.06% | 2.00% | 0.77% | 2.00% | 1.20% |
ViewRay's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VRAY's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ViewRay SG&A Forecast
| Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 17 | 13 | 18 | 19 | 9 | 19 | 9 | 14 | 11 | 12 |
| SG&A | - | $19.57M | $22.30M | $19.70M | $18.49M | $21.61M | $19.99M | $13.09M | $8.22M | $7.60M |
| Avg Forecast | - | - | $21.92M | - | - | - | $10.00M | $17.09M | - | - |
| High Forecast | - | - | $26.30M | - | - | - | $12.00M | $20.50M | - | - |
| Low Forecast | - | - | $17.53M | - | - | - | $8.00M | $13.67M | - | - |
| Surprise % | - | - | 1.02% | - | - | - | 2.00% | 0.77% | - | - |
ViewRay's average Quarter SG&A projection for Mar 24 is -, based on 17 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to VRAY last annual SG&A of $19.57M (Mar 23).
ViewRay EPS Forecast
| Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 17 | 13 | 18 | 19 | 9 | 19 | 9 | 14 | 11 | 12 |
| EPS | - | $-0.17 | $-0.15 | $-0.13 | $-0.18 | $-0.17 | $-0.38 | $-0.11 | $-0.87 | $-0.38 |
| Avg Forecast | $-0.25 | $-0.23 | $-0.18 | $-0.18 | $-0.17 | $-0.17 | $-0.11 | $-0.26 | $-0.11 | $-0.25 |
| High Forecast | $-0.20 | $-0.18 | $-0.14 | $-0.14 | $-0.14 | $-0.14 | $-0.09 | $-0.21 | $-0.09 | $-0.20 |
| Low Forecast | $-0.31 | $-0.28 | $-0.21 | $-0.22 | $-0.20 | $-0.20 | $-0.13 | $-0.31 | $-0.13 | $-0.30 |
| Surprise % | - | 0.74% | 0.83% | 0.72% | 1.06% | 1.00% | 3.45% | 0.42% | 7.91% | 1.52% |
According to undefined Wall Street analysts, ViewRay's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VRAY previous annual EPS of $NaN (undefined).
ViewRay Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VRAY | ViewRay | $0.03 | $6.25 | 20733.33% | Buy |
| INGN | Inogen | $10.33 | $26.00 | 151.69% | Buy |
| DCTH | Delcath Systems | $9.41 | $22.00 | 133.79% | Buy |
| SGHT | Sight Sciences | $3.98 | $9.00 | 126.13% | Hold |
| ESTA | Establishment Labs | $39.32 | $78.00 | 98.37% | Buy |
| ATEC | Alphatec | $9.13 | $16.94 | 85.54% | Buy |
| NPCE | NeuroPace | $9.15 | $12.88 | 40.77% | Buy |
| OFIX | Orthofix Medical | $18.64 | $24.00 | 28.76% | - |
| AVNS | Avanos Medical | $19.49 | $23.00 | 18.01% | Hold |
| CVRX | CVRx | $14.20 | $16.33 | 15.00% | Buy |
| AORT | Artivion | $27.21 | $30.60 | 12.46% | Buy |
| HSCS | Heart Test Laboratories | $2.70 | $3.00 | 11.11% | Buy |